miR‑654‑3p suppresses cell viability and promotes apoptosis by targeting RASAL2 in non‑small‑cell lung cancer

Xiong,Jie; Xing,Shigang; Dong,Zheng; Niu,Lei; Xu,Qinghua; Li,Yusheng; Liu,Pingyi; Yang,Peixia

doi:10.3892/mmr.2020.11763

miR‑654‑3p suppresses cell viability and promotes apoptosis by targeting RASAL2 in non‑small‑cell lung cancer

Authors:
- Jie Xiong
- Shigang Xing
- Zheng Dong
- Lei Niu
- Qinghua Xu
- Yusheng Li
- Pingyi Liu
- Peixia Yang
View Affiliations

Affiliations: Department of Respiratory Medicine, Linyi Central Hospital, Linyi, Shandong 276400, P.R. China, Department of Clinical Laboratory, Linyi Central Hospital, Linyi, Shandong 276400, P.R. China
Published online on: December 8, 2020 https://doi.org/10.3892/mmr.2020.11763
Article Number: 124
Copyright: © Xiong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small‑cell lung cancer (NSCLC) accounts for 80% of lung cancer cases, and is the leading cause of cancer‑associated mortality worldwide. The present study aimed to investigate the roles of microRNA (miR)‑654‑3p in NSCLC. The expression levels of miR‑654‑3p and its target ras protein activator like 2 (RASAL2) mRNA were determined by reverse transcription‑quantitative polymerase chain reaction; protein expression was analyzed by western blotting. Plasmids expressing miR‑654‑3p mimics were constructed and transfected into A549 cells. In addition, the viability and apoptotic rate of cells were analyzed by an MTT assay and flow cytometry, respectively. A luciferase reporter assay was performed to verify whether RASAL2 is a target of miR‑654‑3p. Downregulated miR‑654‑3p and upregulated RASAL2 expression were observed in tumor tissues and cells. Cell viability was suppressed and the apoptotic rate was increased in the miR‑654‑3p mimics‑transfected cells compared with the control. Luciferase activity was decreased in the RASAL2‑3' untranslated region‑wild type group treated with miR‑654‑3p mimics. Furthermore, the present study revealed that overexpression of miR‑654‑3p could suppress the viability and induce the apoptosis of cells by targeting RASAL2 in NSCLC. The present findings may contribute to developments in the treatment of NSCLC.

View Figures

View References

1	Huang G, Sun X, Liu D, Zhang Y, Zhang B, Xiao G, Li X, Gao X, Hu C, Wang M, et al: The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: A meta-analysis. Oncotarget. 9:4239–4248. 2018. View Article : Google Scholar : PubMed/NCBI
2	Quintanal-Villalonga Á, Ojeda-Márquez L, Marrugal Á, Yagüe P, Ponce-Aix S, Salinas A, Carnero A, Ferrer I, Molina-Pinelo S and Paz-Ares L: The FGFR4-388arg variant promotes lung cancer progression by N-cadherin induction. Sci Rep. 8:23942018. View Article : Google Scholar : PubMed/NCBI
3	Gouvinhas C, De Mello RA, Oliveira D, Castro-Lopes JM, Castelo-Branco P, Dos Santos RS, Hespanhol V and Pozza DH: Lung cancer: A brief review of epidemiology and screening. Future Oncol. 14:567–575. 2018. View Article : Google Scholar : PubMed/NCBI
4	Rios J, Gosain R, Goulart BH, Huang B, Oechsli MN, McDowell JK, Chen Q, Tucker T and Kloecker GH: Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity. Cancer Manag Res. 10:167–175. 2018. View Article : Google Scholar : PubMed/NCBI
5	Song YJ, Gao XH, Hong YQ and Wang LX: Direct bilirubin levels are prognostic in non-small cell lung cancer. Oncotarget. 9:892–900. 2018. View Article : Google Scholar : PubMed/NCBI
6	Lan H, Lu H, Wang X and Jin H: MicroRNAs as potential biomarkers in cancer: Opportunities and challenges. Biomed Res Int. 2015:1250942015. View Article : Google Scholar : PubMed/NCBI
7	Van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY and Van Laere SJ: Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 17:212015. View Article : Google Scholar : PubMed/NCBI
8	Zhang XY, Liu DJ, Yuan RB, Zhang DH, Li SR, Zhang SH and Zhang LY: Low expression of miR-597 is correlated with tumor stage and poor outcome in breast cancer. Eur Rev Med Pharmacol Sci. 22:456–460. 2018.PubMed/NCBI
9	Xu C, Zheng Y, Lian D, Ye S, Yang J and Zeng Z: Analysis of microRNA expression profile identifies novel biomarkers for non-small cell lung cancer. Tumori. 101:104–110. 2015. View Article : Google Scholar : PubMed/NCBI
10	Shi GL, Chen Y, Sun Y, Yin YJ and Song CX: Significance of serum microRNAs in the auxiliary diagnosis of non-small cell lung cancer. Clin Lab. 63:133–140. 2017. View Article : Google Scholar : PubMed/NCBI
11	Geraldo MV, Nakaya HI and Kimura ET: Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer. Oncotarget. 8:9597–9607. 2017. View Article : Google Scholar : PubMed/NCBI
12	Teferedegne B, Macauley J, Foseh G, Dragunsky E, Chumakov K, Murata H, Peden K and Lewis AM Jr: MicroRNAs as potential biomarkers for VERO cell tumorigenicity. Vaccine. 32:4799–4805. 2014. View Article : Google Scholar : PubMed/NCBI
13	Hui K, Gao Y, Huang J, Xu S, Wang B, Zeng J, Fan J, Wang X, Yue Y, Wu S, et al: RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer. Cell Death Dis. 8:e26002017. View Article : Google Scholar : PubMed/NCBI
14	Maertens O and Cichowski K: An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. Adv Biol Regul. 55:1–14. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wang Z, Wang J, Su Y and Zeng Z: RASAL2 inhibited the proliferation and metastasis capability of nasopharyngeal carcinoma. Int J Clin Exp Med. 8:18765–18771. 2015.PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Fang JF, Zhao HP, Wang ZF and Zheng SS: Upregulation of RASAL2 promotes proliferation and metastasis, and is targeted by miR-203 in hepatocellular carcinoma. Mol Med Rep. 15:2720–2726. 2017. View Article : Google Scholar : PubMed/NCBI
18	Olsen SN, Wronski A, Castaño Z, Dake B, Malone C, De Raedt T, Enos M, DeRose YS, Zhou W, Guerra S, et al: Loss of RasGAP tumor suppressors underlies the aggressive nature of luminal B breast cancers. Cancer Discov. 7:202–217. 2017. View Article : Google Scholar : PubMed/NCBI
19	Jia Z, Liu W, Gong L and Xiao Z: Downregulation of RASAL2 promotes the proliferation, epithelial-mesenchymal transition and metastasis of colorectal cancer cells. Oncol Lett. 13:1379–1385. 2017. View Article : Google Scholar : PubMed/NCBI
20	Shen H, Wu X, Zhang Y, Deng G, Ma J, Qu Y and Zeng S: Expression of RASAL2 in hepatocellular carcinoma and the clinical significance. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 40:250–255. 2015.(In Chinese). PubMed/NCBI
21	Yan M, Li X, Tong D, Han C, Zhao R, He Y and Jin X: miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer. Oncol Rep. 36:65–71. 2016. View Article : Google Scholar : PubMed/NCBI
22	Noto S, Maeda T, Hattori S, Inazawa J, Imamura M, Asaka M and Hatakeyama M: A novel human RasGAP-like gene that maps within the prostate cancer susceptibility locus at chromosome 1q25. FEBS Lett. 441:127–131. 1998. View Article : Google Scholar : PubMed/NCBI
23	Li N and Li S: RASAL2 promotes lung cancer metastasis through epithelial-mesenchymal transition. Biochem Biophys Res Commun. 455:358–362. 2014. View Article : Google Scholar : PubMed/NCBI